Tamoxifen Mechanism estrogen antagonist in breast estrogen agonist in endometrium, bone Indications estrogen-receptor positive breast cancer Toxicity ↑ risk of DVTs ↑ risk of endometrial cancer secondary to agonist activity induces menopause hot flashes prevents osteoporosis secondary to agonist action in bone Raloxifene Mechanism estrogen antagonist in breast estrogen agonist in bone Indications osteoporosis in menopausal women Toxicity ↑ risk of DVTs induces menopause hot flashes NO ↑ risk of endometrial cancer secondary to antagonist activity in endometrium
QUESTIONS 1 of 2 1 2 Previous Next Sorry, this question is for PEAK Premium Subscribers only Upgrade to PEAK (M1.RP.12.106) A 46-year-old female presents with a primary complaint of irregular menstrual bleeding that has persisted for the last several months. Her medical history consists of 2 full-term pregnancies and invasive ductal carcinoma of the breast that was successfully treated one year ago. After an appropriate evaluation, she is given a diagnosis of type 1 endometrioid adenocarcinoma. Which of the following factors most likely increased this patient’s risk for developing this cancer? QID: 100407 Type & Select Correct Answer 1 Administration of raloxifene in the treatment of her previous breast cancer 8% (24/309) 2 The patient is 46-years-old and has yet to enter menopause 5% (14/309) 3 Combined oral contraceptive use from the age of 32 to 42 7% (23/309) 4 The patient’s two previous pregnancies 4% (13/309) 5 Tamoxifen regimen used to treat her previous breast cancer 73% (225/309) M 4 Question Complexity E Question Importance Select Answer to see Preferred Response SUBMIT RESPONSE 5 Review Tested Concept Review Full Topic
All Videos (0) Reproductive | Selective Estrogen Receptor Modulators (SERMs) Reproductive - Selective Estrogen Receptor Modulators (SERMs) Listen Now 10:15 min 5/14/2022 6 plays 0.0 (0)